Tomasz Huzarski

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations

Pharmacy, Oncology, Pharmacotherapy +14

Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer

Andrew Tutt, Judy E. Garber, Bella Kaufman et al. · New England Journal of Medicine · 2021 · 1.7K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies

Xiaohong R. Yang, Jenny Chang‐Claude, Ellen L. Goode et al. · JNCI Journal of the National Cancer Institute · 2010 · 716 citations · Full text

Medicine, Cancer Biology, Oncology +16

Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a <i>BRCA1</i> or <i>BRCA2</i> Mutation

Amy Finch, Jan Lubiński, Pål Møller et al. · Journal of Clinical Oncology · 2014 · 655 citations · Full text

Medicine, Gynecology, Oncology +17

CHEK2 Is a Multiorgan Cancer Susceptibility Gene

Cezary Cybulski, Bohdan Górski, Tomasz Huzarski et al. · The American Journal of Human Genetics · 2004 · 555 citations · Full text

Medicine, Molecular Genetics, Oncology +9